APP and Alzheimer disease: However, in the more general human AD population that does not have this APP mutation inducing rapid fibrillarization, the functional consequence of this differential gene expression may result in slower plaque accumulation as seen in the 3xTg and Tg2576 AD mouse models when treated with the C5aR1 antagonist, PMX205 [7].